Bristol-Myers Squibb Company (BMY)

79.87 -0.08%
Dec 09 close; Powered by Koyfin
Pros
Company’s profitability is improving
Forward dividend yield higher than the industry and sector averages
Forward P/E ratio low relative to industry peers
Buy analyst rating
Cons
Stock price high relative to the 52-week range
Revenue growth lower than the industry and sector averages
Average analyst stock price below current stock price

Pros

  1. BMY profitability is improving. The YoY profit margin change was 17.10 percentage points. See BMY profitability chart.
  2. BMY forward dividend yield is 2.90%, higher than the industry (2.20%) and sector (0.20%) forward dividend yields. See BMY forward dividend chart.
  3. BMY forward P/E ratio is 9.94, which is low compared to its industry peers’ P/E ratios. See BMY forward P/E ratio chart.
  4. BMY average analyst rating is Buy. See BMY analyst rating chart.

Cons

  1. BMY stock price ($80.88) is at the 52-week high. Perhaps now is a good time to sell? See BMY price chart.
  2. BMY quarterly revenue growth was -3.50%, lower than the industry and sector average revenue growth (11.37% and 6.06%, respectively). See BMY revenue growth chart.
  3. BMY average analyst price target ($80.33) is below its current price ($80.88). See BMY price target chart.